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M  proteins  project  as  a-helical  coiled-coil  fibrils  from  the  cell  surface  of 
Streptococcus pyogenes (1, 2).  These surface fibrils render the organisms resistant 
to  ingestion  and  killing  by blood phagocytes (3).  The  antiphagocytic  effect is 
neutralized by type-specific antibodies directed against the M protein. In addition 
to the type-specific antibodies,  certain  M  proteins evoke crossreactive immune 
responses against  sarcolemmal  membranes  of cardiac  tissue  (4,  5) and  muscle 
myosin  (6).  The  latter  findings  have  hampered  efforts  to  develop  M  protein 
vaccines against rheumatogenic strains of S. pyogenes because of the fear that the 
vaccines may trigger rather  than  prevent acute rheumatic  fever and rheumatic 
heart disease.  In an attempt to avoid heart crossreactive epitopes, we prepared 
vaccines  from  native  and  chemically  synthesized  subpeptide  fragments  of  M 
protein.  We found that  selected synthetic peptides copying known amino  acid 
sequences  of different  M  proteins  evoked  type-specific  protective  immunity 
against the related streptococci without stimulating heart crossreactive immune 
responses (7-13). In this paper, we report that hybrid peptides containing copies 
of selected regions of two different serotypes of M protein synthesized in tandem 
evoke  protective  but  not  heart  crossreactive  immune'responses  against  both 
serotypes of S. pyogenes.  Our findings may have bearing not only on the devel- 
opment of safe,  multivalent  M protein  vaccines to protect against the  many M 
serotypes of streptococci  giving  rise  to  acute  rheumatic  fever and  rheumatic 
heart disease, but also on the development of multivalent hybrid vaccines against 
a variety of other infectious agents. 
Materials and Methods 
Natural and Synthetic Peptides of  Streptococcal M Protein.  Natural polypeptide fragments 
of M protein were isolated and purified from limited digests of types 5 and 24 M proteins 
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as described (14,  15). The polypeptides designated pep M5 and pep M24 were judged to 
be pure by SDS gel electrophoresis and quantitative amino acid analysis  (16).  Synthetic 
copies of the  COOH-terminus,  23-35, of the cyanogen bromide-derived fragment  7 
(CB7) of type 24 M protein (17),  and the NH~-terminus,  1-20, of pep M5 (9) were the 
same as  those  used  and  reported in previous studies  (9,  10).  They are  designated  S- 
CB7(23-35)C and S-M5(1-20), respectively. In addition, two hybrid peptides, S-M5(1- 
20)-S-CB7(23-35)C and S-M5(1-20)-S-CB7(19-34) were synthesized by the solid-phase 
method of Merrifield (18)  as  previously described  (10).  The  synthetic peptides  were 
purified by gel filtration on columns of Sephadex G50, and further purified as needed by 
reverse-phase HPLC on Ultrasphere ODS (Whatman Inc., Clifton, NJ) (10). The purified 
peptides were analyzed for purity and composition by quantitative amino acid analysis 
and automated Edman degradation to the penultimate amino acid residue (8,  17). 
Rabbit Immunization.  Sets of three New Zealand White rabbits (2 kg) were each injected 
with a  50  nmol dose of the respective hybrid synthetic peptides emulsified in CFA  as 
described (9,  10).  Rabbits  were bled  before, and at  2-wk  intervals after the  primary 
immunizing dose. At 4, 8, and 10 wk, each rabbit was injected with a 50 nmol s.c. booster 
dose of the same peptide in PBS (0.02  M phosphate with 0.15 M  NaCI,  pH 7.4).  The 
preparation of antisera against S-M5(1-20), S-CB7(23-35)C, pep M5, and pep M24 was 
previously reported (9, 10). All sera were heat-inactivated at 56°C for 30 min and stored 
in sterile vials at 4 ° C. 
Assays of  Anti-M Protein Antibodies.  The rabbit sera were assayed for antibodies against 
M  protein by ELISA, opsonophagocytic assays,  and indirect bactericidal assays,  as de- 
scribed (19). The serotype specificity of the antibodies raised against the hybrid peptides 
was determined by assaying the antisera against types 6 and  19 streptococci, as well as 
against types 5 and 24 organisms in opsonophagocytic assays (19). 
Assays for M  Protein  Epitopes.  The  presence of protective M  protein epitopes  was 
determined by the ability of natural and synthetic polypeptides to inhibit the opsonization 
of types 5 and 24 streptococci by antisera raised against the hybrid peptide S-M5(1-20)- 
S-CB7(23-35)C. The antisera (0.1 ml) were mixed with an equal volume of PBS containing 
100 ttM synthetic peptide. After incubation for 30 min at 37°C, the mixture was used in 
opsonophagocytosis tests of types 5 and 24 streptococci (19). 
Results 
The compositions of the hybrid peptides, S-M5(1-20)-S-CB7(23-35)C and S- 
M5(1-20)-S-CB7(19-34)  were  confirmed by  quantitative  amino  acid  analysis. 
Automated Edman degradation to the penultimate residue gave the amino acid 
sequence of S-M5(1-20)-S-CB7(23-35)C shown in Fig.  1. 
FIGURE  l. 
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Amino acid sequence of S-M5(1-20)-S-CB7(23-35)C. 
The COOH-terminal cysteine residue was added so that the peptide could form 
dimers and thereby potentially increase its immunogenicity. The sequence of S- 
M5(1-20)-S-CB7(19-34) was found to be identical except for an additional four 
residues,  Ala-Leu-Ala-Ala,  between  the tyrosine residue at position 20 and  the 
arginine residue at position 21, and the deletion of the COOH-terminal  methi- 
onine and cysteine residues. The latter peptide was synthesized in an attempt to BEACHEY ET  AL.  1453 
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FIGURE 2.  Immune responses in three rabbits  (F'I, O, O) as measured  by ELISA against 
purified pepsin extracts of types 5 and 24 M proteins (pep M5 and pep M24) (12, 13) (left) or 
by opsonic antibody assays against types 5 and type 24 streptococci (right) after immunization 
with 50 nmol of S-M5(1-20)-S-CB7(23-35)C emulsified in CFA, followed 4, 8, and  10 wk 
later by the same dose in PBS. Each symbol represents a different rabbit. Sera collected at 2- 
wk intervals were assayed for antibodies to types 5 and 24 M proteins (pep M5 and pep M24) 
adsorbed to the walls of plastic cuvettes by ELISA. ELISA titers are expressed as the reciprocal 
of the highest dilution of antiserum giving an absorption >0.1 at 405 nm. Opsonic antibodies 
were assayed as described in Materials and Methods. The results of the opsonophagocytosis 
tests were confirmed by indirect bactericidal tests performed as previously described (19). The 
M protein type specificity was confirmed by the failure of the M5-M24 hybrid peptide immune 
sera to promote phagocytosis and killing of heterologous types 1, 6, 18, and 19 streptococci. 
maintain  the  maximum  a-helical  potential  of the  hybrid  peptide  should  this 
secondary structural  feature play a role in protective immunogenicity. 
Each of three rabbits injected with 50 nmol of S-M5(1-20)-S-CB7(23-35)Cys, 
followed by booster injections with the  same dose in saline at 4,  8,  and  10  wk, 
developed  high  titers  of serum antibodies  against  both  type  5  and  type  24  M 
protein  as measured  by  ELISA, and  against  type  5  and  type  24 S.  pyogenes  as 
measured  by  opsonophagocytic  tests  (Fig.  2).  The  immune  sera  were  able  to 
promote not only phagocytosis but also killing of both types 5 and 24 streptococci 
(Fig.  2),  indicating  that  the  antibodies  evoked by the  synthetic  hybrid  peptide 
recognized  protective antigenic  determinants  of both  M  serotypes exposed on 
the surfaces of the respective serotypes of streptococcal cells. 
Similar  results  were  obtained  with  the  free  synthetic  peptide  S-M5(1-20)-S- 
CB7(19-34).  Even  though  the  latter  peptide  lacks a  COOH-terminal  cysteine 
residue  and  the  potential  to produce  dimeric  hybrid molecules,  it nevertheless 1454  HYBRID  M  PROTEIN  EPITOPES 
TABLE  I 
Type-specific Inhibition of Opsonic Antibodies against Types 5 and 24 Streptococci 
in Sera of Rabbits Immunized with M5-M24 Hybrid Peptide 
Serum used in opsonization tests 
Opsonization (percentage of neutrophils 
with ingested streptococci) 
Type 5 streptococci  Type 24 strepto- 
cocci 
Preimmune  2  0 
Pooled (three rabbits) immune 
anti-S-M5(1-20)-S-CB7(23-35)C 
Uninhibited  80  88 
Inhibited with: 
Type 5 streptococci  2  92 
Type 24 streptococci  82  0 
S-M5(1-20)  0  88 
S-CB7(23-35)C  78  0 
S-M5(1-20)-S-CB7(23-35)C  2  0 
Equal volumes of serum obtained at 12 wk from each of the three immunized rabbits 
(see Fig. 2) were pooled and used in opsonization tests as described in Material and 
Methods. Preimmune  sera obtained  before the first immunizing dose were similarly 
pooled. The tests of inhibition of opsonization were performed by preincubating  0.2 
ml samples of twofold dilutions of the pooled immune serum for 30 min at 37 °C with 
pellets of type 5 or 24 streptococci obtained by centrifuging  5 ml of an  18-h Todd- 
Hewitt  broth  culture  of each  of the  organisms.  After removing  the  organisms by 
centrifugation and membrane filtration (0.45 tzm), the absorbed sera were employed in 
the opsonization tests. The soluble inhibitors were dissolved at a concentration of 100 
~M in PBS, and 0.1 ml of the solutions were incubated with 0.1 ml of pooled immune 
serum for 30 rain at 37 °C before adding the mixture to the phagocytosis tests mixtures. 
The results are expressed as percentage  of neutrophils  ingesting streptococci after 
incubation with human blood, as described in Fig. 2. 
was  capable  of evoking  opsonic  antibodies  against  both  type  5  and  type  24 
streptococci  without  conjugation  to  an  additional  carrier protein.  The  ELISA 
titers, measured at 6  wk against pep M24 were 51,200,  6,400,  and  12,800,  and 
against pep M5 were 400, 6,400 and 12,800 in each of three rabbits, respectively. 
Moreover, the undiluted  sera of the immunized rabbits promoted the opsoniza- 
tion  of both  types 5  and  24 streptococci as follows:  4,  32,  and  52%  for type 5 
streptococci, and 98, 72, and 84% for type 24 streptococci. 
Interestingly,  when  either  of the  hybrid  peptides  was  covalently  linked  to 
tetanus  toxoid  with  glutaraldehyde  (9)  before  immunization,  the  immune  re- 
sponses to type 5  streptococci were essentially the same, whereas those to  type 
24  streptococci  were  totally  suppressed.  For  example,  opsonic  antibody  titers 
against type 5 streptococci 6 wk after immunization with S-M5(1-20)-S-CB7(23- 
35)C were 1:2,  1:4, and  1:16 in each of three rabbits, whereas those against type 
24 streptococci were all <1:2; the undiluted immune sera failed to opsonize type 
24 streptococci. 
The  specificity  of  the  opsonic  antibodies  raised  against  the  unconjugated 
peptide S-M5(1-20)-S-CB7(23-35)C  was determined by immonoabsorption and 
inhibition tests (Table I). Absorption of type 5 or type 24 opsonic antibodies by 
the respective serotypes of whole streptococci was entirely type-specifc. Similarly, BEACHEY  ET  AL.  1455 
the peptide S-M5(1-20), corresponding to a region of type 5 M protein, inhibited 
opsonization only of type 5 streptococci, whereas S-CB7(23-35)C, corresponding 
to  a  region  of type  24  M  protein,  only  inhibited  opsonization  of type  24 
organisms. The hybrid peptide used to immunize the rabbits inhibited opsoni- 
zation of both serotypes (Table I). 
None of the rabbits immunized with either of the synthetic hybrid M protein 
peptides either as the free peptides or as tetanus toxoid conjugates developed 
antibodies crossreactive by immunofluorescence tests  with sarcolemmal mem- 
branes or by ELISA with purified muscle myosin. These results indicate that the 
M protein regions incorporated into the hybrid peptides contain protective but 
not heart crossreactive epitopes. 
Discussion 
Recently, Houghten et al. (20) reported the stimulation of protective immune 
responses against both the heat-labile and heat-stable toxins of Escherichia coli by 
peroral administration of a hybrid peptide containing a  26 amino acid-residue 
copy of the labile toxin joined in tandem to an  18-residue copy of stable toxin. 
However, we believe our studies are the first to show that a  synthetic hybrid 
peptide can raise antibodies that promote the phagocytosis and killing of two 
different bacterial pathogens. Although previous studies (7-13) have shown the 
feasibility of using chemically synthesized copies of M  protein peptides as im- 
munogens, the protective immunity evoked by these peptides has been restricted 
to the single M serotypes from which they were copied. It is true that one may 
produce multivalent vaccines by conjugating more than one synthetic peptide to 
the same carrier (21)  or  by polymerizing them  to  each other (22),  but  these 
approaches raise the problems associated with possible immunosuppression in- 
duced by repeated injections of the same carrier, or the potential toxicity of the 
polymerizing agent. Moreover, the orientation of the protective epitopes is more 
difficult to predict in such polymers. The tandem hybrids, on the other hand, 
have the advantage that the synthetic peptides can be tailored in a predictable 
way so as to render protective epitopes optimally immunoaccessible. 
Of interest was the finding that the hybrid peptides were immunogenic in the 
absence of a  carrier.  Although one might explain the immunogenicity of the 
hybrid containing the cysteine residue at the COOH-terminus on the basis of its 
potential to form dimers 68 residues long, this explanation cannot account for 
the similar degree of immunogenicity of the hybrid peptide lacking the COOH- 
terminal cysteine residue.  The  latter peptide  lacks both  the cysteine and  the 
adjacent methionine residues at the COOH-terminus, but has an additional four 
amino  acid  residues,  Ala-Leu-Ala-Ala,  in  the  middle  of the  molecule.  This 
tetrapeptide is a part of the corresponding region of the natural CB7 fragment 
of type 24 M protein, and it was incorporated for the purpose of preserving the 
o~-helical potential of the hybrid peptide should this structural feature play a role 
in protective immunogenicity. In another study (H. Gras-Masse,  M. Jolivet,  F. 
Audibert,  E.  Beachey, L.  Chedid, and A.  Tarter,  manuscript in  preparation), 
circular dichroism studies show that the latter hybrid has an a-helical structure 
of-20%,  whereas that of the former, containing the COOH-terminal cysteine 
residue, is <6% o~ helix. Because of the strong immunogenicity of the synthetic 1456  HYBRID M PROTEIN EPITOPES 
hybrid containing  virtually no o~-helicity, it is obvious that conservation of this 
structural  feature is not the key to protective immunogenicity of small peptide 
copies of streptococcal  M  proteins.  It  is  possible,  therefore,  that  each  of the 
components of the synthetic hybrids serves as a carrier for the other to present 
the appropriate  epitopes to the  immune  system in an optimally accessible and 
flexible conformation  to stimulate the production of a  repertoire of antibodies 
that will recognize the corresponding conformational adaptations of the natural 
M protein molecule (23). 
The broader implication  of our studies is that one may be able to synthesize 
tandem  hybrids that contain protective epitopes of a  variety of viral,  bacterial, 
and  other  parasitic  agents.  However, there  is  a  limitation  to  the  number  of 
different specificities that  could be incorporated  into a  single-chain  peptide by 
chemical synthesis.  In the future, therefore, one may need to rely on the tools 
of molecular biology. Synthetic or cloned oligonucleotides encoding the desired 
epitopes may be fused in the appropriate  reading frame in tandem to a carrier 
gene (24) that is then transferred into Escherichia coli. Such transformed bacteria 
would produce large quantities  of long, multivalent  hybrid vaccines capable of 
evoking broadly protective immunities against many serious infectious diseases, 
many of which are still fatal or produce sometimes devastating complications. 
Summary 
The protective immunogenicity of a hybrid peptide containing tandem copies 
of types 5 and  24 epitopes was investigated.  Carboxy-terminal  peptides of the 
cyanogen bromide-derived fragment 7 (CB7) of type 24 M protein were chem- 
ically  synthesized,  and  then  extended  to  include  the  first  20  residues  of the 
amino-terminus of type 5 M protein. When emulsified in CFA and injected into 
rabbits without conjugation  to a  carrier,  each of the synthetic hybrid peptides, 
designated  S-M5(1-20)-S-CB7(23-35)C  and  S-M5(1-20)-S-CB(19-34),  evoked 
opsonic antibodies against both types 5 and 24 streptococci without raising heart 
tissue-crossreactive immunity. These results suggest that tandem hybrid peptides 
may provide a  new approach  to the development of multivalent  vaccines,  not 
only to different serotypes of group A streptococci but perhaps also to a variety 
of other infectious agents. 
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